# Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung

> **NCT01236716** · PHASE2 · COMPLETED · sponsor: **Chinese Society of Lung Cancer** · enrollment: 126 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Albumin paclitaxel plus carboplatin
- **DRUG:** Gemcitabine plus carboplatin

## Key facts

- **NCT ID:** NCT01236716
- **Lead sponsor:** Chinese Society of Lung Cancer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2013-12
- **Final completion:** 2014-06
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01236716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01236716, "Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01236716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*